BLAINJECTIONINJECTABLE
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SELARSDI is a monoclonal antibody (mAb) biosimilar of ustekinumab approved by the FDA on April 16, 2024, developed by Alvotech. As a biosimilar to the reference biologic, it targets the same mechanism of action for autoimmune and inflammatory conditions. The product represents a biosimilar entrant in a mature therapeutic class with established clinical utility.
Growth
Early-stage biosimilar in growth phase with moderate competitive intensity (30% pressure) presents opportunity for market penetration specialists and commercial expansion roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SELARSDI offers career growth in biosimilar commercialization, market access, and financial modeling as Alvotech scales a newly approved asset. The role combines early-launch commercial intensity with operational discipline required for biosimilar competitive positioning and reimbursement strategy.
ScientistRevenue Analyst
Worked on SELARSDI at Alvotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.